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Introduction 
Abuse Liability of Tapentadol is Significantly Lower Than Other Schedule II Opioids  
Suzanne K. Vosburg, PhD1, Stevan G. Severtson , PhD1, Jody L. Green, PhD1, Steven P. Kurtz, PhD2, Richard C. Dart, MD, PhD1 
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• Tapentadol is a Schedule II opioid with a combination of μ-opioid activity 
and norepinephrine reuptake inhibition that is used for the management of 
moderate to severe acute and chronic pain. 
• To date, a pattern of relatively low, although not absent, abuse liability has 
been found.  
• This study included intentional abuse exposures reported to poison 
centers and cases of diversion to assess the abuse liability of tapentadol. 
• The abuse and diversion rates for all formulations of tapentadol are 
compared to rates for other Schedule II opioids using data from the 
Researched Abuse, Diversion and Addiction-Related Surveillance 
(RADARS®) System Poison Center and Drug Diversion Programs. 
– The RADARS System Poison Center Program obtains data from individuals within 
the general population and from healthcare providers who are seeking advice 
regarding potential toxic exposures, including exposures to prescription opioids and 
stimulants. 
– The RADARS System Drug Diversion Program conducts a quarterly survey of law 
enforcement investigators on the diversion of prescription opioid and stimulant 
products in their jurisdictions.  
• Cumulative tapentadol rates per population and per dosage units 
dispensed are compared to those for hydrocodone, hydromorphone, 
morphine, oxycodone, and oxymorphone from October 2011 through 
December 2016 using Poisson regression.  
• The ratio of each comparator opioid rate relative to the tapentadol rate is 
presented in Figure 1.  
• There were 92 intentional abuse exposure case reports (calls) involving 
tapentadol products during the study period. Per population, the rate of 
tapentadol intentional abuse was significantly lower than all comparator 
opioids (p<0.001).  
• The rate of tapentadol intentional abuse exposure case reports per 
dosage units dispensed was significantly lower than all comparator 
opioids (p<0.01) except hydrocodone (p=0.002).  
• There were 60 cases of tapentadol diversion during the study period. 
Rates of tapentadol diversion per population and per dosage units 
dispensed were significantly lower than comparator opioids (p<0.001). 
Limitations 
• Population rate findings suggest the overall public health burden of 
tapentadol abuse and diversion is low relative to other Schedule II 
opioids.  
• Diversion  of tapentadol is less frequent than other Schedule II 
opioid products when accounting for drug utilization (dosage units 
dispensed).  
• Rates of tapentadol intentional abuse case reports per dosage units 
dispensed are lower than hydromorphone, morphine, oxycodone, 
and oxymorphone, but greater than hydrocodone.  
• This analysis assesses abuse liability at the opioid molecule level. 
Given differences between the molecules, further research is 
needed to assess the  impact of different formulations (e.g. 
immediate release versus extended release; single-entity or 
combination-products).   
• The Poison Center Program relies on spontaneous reports; 
therefore, the number of cases is underreported and drug 
identification may be inaccurate.  
• Not all parts of the US have prescription drug diversion agencies, 
and thus data are subject to under-reporting and regional 
differences. 
Disclosures 
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Figure 1. Ratio of Comparator Opioids Rates to 
Tapentadol Rates with 95% Confidence Intervals 
Note: Values greater than one indicate a rate higher relative to tapentadol. Confidence intervals that do not overlap 
1 indicate that the tapentadol rate is significantly different than the comparator rate. Dosage units dispensed data 
are based on projections provided by QuintilesIMS™ (Danbury, CT).  
